ArticleOncotarget2015

Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma.

Jiao Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.